Names and pronunciation
(ix′e-kiz′ue-mab) Taltz
PDF page 737
Loading InternPractice…
Drug reference
(ix′e-kiz′ue-mab) Taltz
PDF page 737
Func. class.: Immunosuppressive
PDF page 737
ACTION: A human IgG4 monoclonal antibody that selectively binds to the inter- leukin 17A (IL-17A) cytokine, inhibiting its interaction with the IL-17 receptor. Treatment inhibits the release of proin- flammatory cytokines and chemokines
PDF page 737
USES: The treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or photo- therapy, active psoriatic arthritis
PDF page 737
CONTRAINDICATIONS: Risk of serious hypersensitivity reactions or anaphylaxis Precautions: Breastfeeding, children, Crohn’s disease, immunosuppression, infection, inflammatory bowel disease, pregnancy, tuberculosis, ulcerative coli- tis, vaccination
PDF page 737
SIDE EFFECTS SYST: antibody formation, infection, angioedema INTEG: injection site reaction, urticaria HEMA: neutropenia
PDF page 737
INTERACTIONS • Do not use concurrently with vaccines; immunizations should be brought up-to- date before treatment • Avoid use with immunosuppressives
PDF page 737
DOSAGE AND ROUTES • Adult: SUBCUT 160 mg at week 0 (administered as two 80-mg injections) followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg q4wk; for active psoriatic arthritis maintenance 80 mg q4wk • Available forms: Solution for injec- tion 80 mg/mL, autoinjector 80 mg/mL
PDF page 737
Administer: Subcut route • Administer by subcutaneous injection only • Visually inspect for particulate matter and discoloration before use. The solu- tion should be free of visible particles, clear, and colorless to slightly yellow • Available as a prefilled syringe and as an autoinjector; each device contains 80 mg • Use upper arms, thighs, and any quad- rant of the abdomen for injection sites • Do not use where skin is tender, bruised, erythematous, indurated, or affected by psoriasis; rotate sites with each dose • Does not contain preservatives; dis- card any unused product • Missed doses: If a dose is missed, give as soon as possible. Then, resume dosing at the regular scheduled time • Storage of unopened prefilled sy- ringes and autoinjectors: Protect from light; store refrigerated at 2°C-8°C (36°F-46°F) until time of use. Do not freeze and do not use the injection if it has been frozen. Do not shake
PDF page 737
Assess: • TB: TB testing should be done be- fore use • For injection-site reactions, redness, swelling, pain • Bring immunizations up-to-date be- fore use • Infection: monitor for fever, sore throat, cough; do not use in active infections • Pregnancy/breastfeeding: avoid in pregnancy and breastfeeding
PDF page 737
Evaluate: Therapeutic response: de creased psoriasis Patient and caregiver information: • That product must be continued for prescribed time to be effective, to use as prescribed • Not to receive vaccinations during treatment • Infection: to notify prescriber of pos- sible infections, respiratory or other, or of allergic reactions • Injection techniques and disposal of equipment, not to reuse needles, syringes
PDF page 737
CLINICAL CONSIDERATIONS
PDF page 737
PHARMACOKINETICS I Half-life is 13 days; bioavailability 60% to 81%, injection in the thigh achieved higher bioavailability; peak 4 days
PDF page 737
• Adult: SUBCUT 160 mg at week 0 (administered as two 80-mg injections) followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg q4wk; for active psoriatic arthritis maintenance 80 mg q4wk
PDF page 737
• Available forms: Solution for injec- tion 80 mg/mL, autoinjector 80 mg/mL
PDF page 737